The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded Genetobe Inc., a Michigan-based biotechnology company, a $613,558 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The purpose of this 1-year grant is for Genetobe to develop novel, selective sodium-dependent glucose cotransporter 1 (SGLT1) inhibitor compounds as an adjunctive therapy for treating cystic fibrosis (CF) associated metabolic disorders, including CF-associated liver disease (CFLD) and CF-related diabetes (CFRD). The project leverages Genetobe's expertise in AI-assisted drug design and prior successes in developing small molecule therapeutics. The research will involve preclinical studies in a CF rabbit model to evaluate the efficacy of SGLT1 inhibition in combination with the CF drug Trikafta in alleviating metabolic complications, with the goal of introducing a first-in-class SGLT1 selective compound as a potential adjunctive therapy for CF patients.
Generated 1/28/25, 11:06 AM